Topgen closes RMB120m Series C round, focuses on precision medicine

Topgen recently announced that it has closed a Series C round of financing totaling 120 million yuan.

Topgen recently announced that it has closed a Series C round of financing totaling 120 million yuan.

The round was jointly invested by The Chinese Academy of Sciences Holdings, Shenzhen Guoke Ruihua Equity Fund, Zhuji Jingkai Chuangyou Equity Fund and other institutions.

The proceeds will be used for the layout of the third-party laboratory network, research and development of in vitro diagnostic reagents and capacity upgrade, and continue to deepen the company’s dual-drive business model of “service + product”.

Topgen has successfully established a molecular diagnostic product line based on high-throughput sequencing, real-time fluorescence quantitative PCR, digital PCR and other cutting-edge technologies.

The applications involve core areas such as tumor-associated diagnosis, early screening, pathogen detection, personalized medicine, genetic testing, and therapeutic efficacy monitoring, realizing the overall coverage of precision medicine.

To date, Topgen has five medical laboratories in Zhejiang, Shanghai, Anhui, Chongqing, and Shandong, 1500 square meters of medical device GMP production workshop.

The hospital has established 50 precision medical centers, with customers in more than 830 3A hospitals in 23 provinces, cities and autonomous regions.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/07/19/topgen-closes-rmb120m-series-c-round-focuses-on-precision-medicine/.

Leave a Reply

Please Login to Comment